C

CTI Biopharma Corp
F:CEPS

Watchlist Manager
CTI Biopharma Corp
F:CEPS
Watchlist
Price: 28 EUR Market Closed
Market Cap: 3.7B EUR

FCF Margin
Free Cash Flow Margin

-108.6%
Current
-647%
Average
-7.5%
Industry

FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

FCF Margin
-108.6%
=
Free Cash Flow
-82.3m
/
Revenue
75.8m

FCF Margin Across Competitors

CTI Biopharma Corp
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.

CEPS Intrinsic Value
Not Available
C
What is Free Cash Flow Margin?

FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

FCF Margin
-108.6%
=
Free Cash Flow
-82.3m
/
Revenue
75.8m
What is the FCF Margin of CTI Biopharma Corp?

Based on CTI Biopharma Corp's most recent financial statements, the company has FCF Margin of -108.6%.

Back to Top